MTNB
Income statement / Annual
Last year (2023), Matinas BioPharma Holdings, Inc.'s total revenue was $1.10 M,
a decrease of 65.62% from the previous year.
In 2023, Matinas BioPharma Holdings, Inc.'s net income was -$22.94 M.
See Matinas BioPharma Holdings, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$1.10 M
|
$3.19 M
|
$33,333.00
|
$158,333.00
|
$90,000.00
|
$119,750.00
|
$149,687.00
|
$0.00
|
$194,494.00
|
$0.00
|
| Cost of Revenue |
$14.49 M |
$16.68 M |
$781,491.00 |
$14.36 M |
$11.23 M |
$6.79 M |
$9.01 M |
$52,644.00 |
$5.29 M |
$5.18 M |
| Gross Profit |
-$13.39 M |
-$13.49 M |
-$748,158.00 |
-$14.20 M |
-$11.14 M |
-$6.67 M |
-$8.86 M |
-$52,644.00 |
-$5.10 M |
-$5.18 M |
| Gross Profit Ratio |
-12.22 |
-4.23 |
-22.44 |
-89.69 |
-123.83 |
-55.68 |
-59.2 |
0 |
-26.21 |
0 |
| Research and Development
Expenses |
$14.49 M
|
$16.68 M
|
$14.58 M
|
$14.36 M
|
$11.24 M
|
$6.79 M
|
$9.01 M
|
$3.95 M
|
$5.29 M
|
$5.18 M
|
| General & Administrative
Expenses |
$10.37 M
|
$11.10 M
|
$10.18 M
|
$10.01 M
|
$7.78 M
|
$7.98 M
|
$7.64 M
|
$4.31 M
|
$4.81 M
|
$5.29 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$10.37 M
|
$11.10 M
|
$10.18 M
|
$10.01 M
|
$7.78 M
|
$7.98 M
|
$7.64 M
|
$4.31 M
|
$4.81 M
|
$5.29 M
|
| Other Expenses |
$0.00 |
-$16.68 M |
$122,870.00 |
$686,425.00 |
$541,000.00 |
$56,552.00 |
$22,032.00 |
-$16,505.00 |
$19,627.00 |
-$25,173.00 |
| Operating Expenses |
$24.86 M |
$11.10 M |
$24.77 M |
$24.36 M |
$19.01 M |
$14.77 M |
$16.65 M |
$8.26 M |
$10.11 M |
$10.46 M |
| Cost And Expenses |
$24.86 M |
$27.78 M |
$24.77 M |
$24.36 M |
$19.01 M |
$14.77 M |
$16.65 M |
$8.26 M |
$10.11 M |
$10.46 M |
| Interest Income |
$0.00 |
$0.00 |
$3,000.00 |
$7,000.00 |
$11,700.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$941,000.00
|
$898,000.00
|
$781,491.00
|
$774,587.00
|
$780,816.00
|
$218,308.00
|
$100,605.00
|
$52,644.00
|
$43,502.00
|
$41,581.00
|
| EBITDA |
-$22.83 M
|
-$24.23 M
|
-$24.46 M
|
-$23.92 M
|
-$18.59 M
|
-$14.43 M
|
-$16.40 M
|
-$8.20 M
|
-$9.87 M
|
-$10.42 M
|
| EBITDA Ratio |
-20.83 |
-8.81 |
-781.9 |
-159.66 |
-221.42 |
-120.49 |
-113.83 |
0 |
-54.63 |
0 |
| Operating Income Ratio
|
-21.68
|
-7.71
|
-742.05
|
-152.88
|
-210.23
|
-122.31
|
-110.25
|
0
|
-50.96
|
0
|
| Total Other
Income/Expenses Net |
$824,000.00
|
$3.59 M
|
$1.45 M
|
$1.76 M
|
$1.55 M
|
$56,552.00
|
$658,958.00
|
$658,396.00
|
$776,099.00
|
$243,954.00
|
| Income Before Tax |
-$22.94 M |
-$21.00 M |
-$23.28 M |
-$22.45 M |
-$17.37 M |
-$14.59 M |
-$15.84 M |
-$7.60 M |
-$9.14 M |
-$10.22 M |
| Income Before Tax Ratio
|
-20.93
|
-6.59
|
-698.51
|
-141.77
|
-193.03
|
-121.84
|
-105.84
|
0
|
-46.97
|
0
|
| Income Tax Expense |
$0.00 |
-$7.98 M |
-$2.11 M |
-$1.85 M |
-$1.79 M |
-$506,920.00 |
-$356,956.00 |
-$674,901.00 |
-$756,472.00 |
-$269,127.00 |
| Net Income |
-$22.94 M |
-$13.02 M |
-$21.17 M |
-$20.60 M |
-$15.59 M |
-$14.08 M |
-$15.49 M |
-$7.60 M |
-$9.14 M |
-$10.22 M |
| Net Income Ratio |
-20.93 |
-4.08 |
-635.21 |
-130.1 |
-173.17 |
-117.6 |
-103.46 |
0 |
-46.97 |
0 |
| EPS |
-5.28 |
-3 |
-5.04 |
-5.23 |
-5.37 |
-7.18 |
-8.56 |
-6.59 |
-8.87 |
-15.93 |
| EPS Diluted |
-5.28 |
-3 |
-5.04 |
-5.23 |
-5.37 |
-7.18 |
-8.56 |
-6.59 |
-8.87 |
-15.93 |
| Weighted Average Shares
Out |
$4.35 M
|
$4.34 M
|
$4.20 M
|
$3.94 M
|
$2.90 M
|
$1.96 M
|
$1.81 M
|
$1.15 M
|
$1.03 M
|
$641,534.34
|
| Weighted Average Shares
Out Diluted |
$4.35 M
|
$4.34 M
|
$4.20 M
|
$3.94 M
|
$2.90 M
|
$1.96 M
|
$1.81 M
|
$1.15 M
|
$1.03 M
|
$641,534.34
|
| Link |
|
|
|
|
|
|
|
|
|
|
